Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Liabilities (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Total Liabilities data on record, last reported at $125.9 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 34.52% year-over-year to $125.9 million; the TTM value through Sep 2025 reached $125.9 million, up 34.52%, while the annual FY2024 figure was $105.7 million, 41.09% up from the prior year.
  • Total Liabilities reached $125.9 million in Q3 2025 per NWBO's latest filing, up from $116.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $385.7 million in Q1 2021 and bottomed at $4.9 million in Q3 2023.
  • Average Total Liabilities over 5 years is $143.3 million, with a median of $116.2 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: tumbled 96.08% in 2023, then skyrocketed 1793.18% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $164.2 million in 2021, then fell by 16.93% to $136.4 million in 2022, then plummeted by 45.06% to $74.9 million in 2023, then soared by 41.09% to $105.7 million in 2024, then rose by 19.06% to $125.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $125.9 million in Q3 2025, $116.2 million in Q2 2025, and $112.3 million in Q1 2025.